These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. 1592 (abacavir): do not rechallenge after hypersensitivity reaction. James JS AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916 [TBL] [Abstract][Full Text] [Related]
6. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950 [TBL] [Abstract][Full Text] [Related]
7. Current trends in screening across ethnicities for hypersensitivity to abacavir. Rodriguez-Nóvoa S; Soriano V Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539 [TBL] [Abstract][Full Text] [Related]
9. Abacavir warning: certain respiratory symptoms can indicate hypersensitivity reaction. AIDS Treat News; 2000 Feb; (No 337):7-8. PubMed ID: 11367210 [TBL] [Abstract][Full Text] [Related]
10. No rechallenge for abacavir. AIDS Patient Care STDS; 2004 Dec; 18(12):737. PubMed ID: 15669129 [No Abstract] [Full Text] [Related]
11. Understanding drug hypersensitivity: what to look for when prescribing abacavir. Hetherington S AIDS Read; 2001 Dec; 11(12):620-2. PubMed ID: 11806176 [TBL] [Abstract][Full Text] [Related]
12. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508 [TBL] [Abstract][Full Text] [Related]
13. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. Waters LJ; Mandalia S; Gazzard B; Nelson M AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891 [TBL] [Abstract][Full Text] [Related]
14. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients. Bellagamba R; Tommasi C; De Marco M; Narciso P J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915 [No Abstract] [Full Text] [Related]
15. Identification of abacavir hypersensitivity reaction in health care claims data. Nordstrom BL; Norman HS; Dube TJ; Wilcox MA; Walker AM Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):289-96. PubMed ID: 17245797 [TBL] [Abstract][Full Text] [Related]
16. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects. King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870 [TBL] [Abstract][Full Text] [Related]
18. Large lymphadenopathies complicating the abacavir hypersensitivity reaction. García JT; González PR; Hernández-Mora MG; Novoa SR; Quintana FB; Lahoz JG; Vázquez VS AIDS; 2007 Oct; 21(16):2254-6. PubMed ID: 18090059 [No Abstract] [Full Text] [Related]
19. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424 [TBL] [Abstract][Full Text] [Related]
20. Hypersensitivity reactions reported with abacavir. AIDS Patient Care STDS; 1998 May; 12(5):405-6. PubMed ID: 11361980 [No Abstract] [Full Text] [Related] [Next] [New Search]